FDA grants full approval to Tecelra for unresectable or metastatic synovial sarcoma, expanding use to adolescents and broadening dosing range.
Written By: Disha Jadhao, BPharm
Reviewed By: Pharmacally Editorial Team
The U.S. Food and Drug Administration (FDA) has granted traditional approval to Tecelra (afamitresgene autoleucel) after reviewing confirmatory clinical data that verified its clinical benefit in patients with unresectable or metastatic synovial sarcoma. The approval converts the therapy’s August 2024 accelerated approval to full approval and expands its indication to include pediatric patients aged 12 years and older. The updated label also broadens the recommended dose range to 1.62 × 10⁹ to 10 × 10⁹ MAGE-A4 T-cell receptor (TCR)-positive T cells.
Tecelra is an autologous genetically engineered T-cell receptor (TCR) therapy that targets the MAGE-A4 tumor antigen. The treatment is intended for patients with unresectable or metastatic synovial sarcoma who have previously received chemotherapy, carry eligible HLA-A*02 alleles, and have tumors expressing the MAGE-A4 antigen confirmed by an FDA-approved or cleared companion diagnostic test. Synovial sarcoma is a rare and aggressive soft tissue cancer with limited treatment options after chemotherapy, creating a significant unmet clinical need.
Confirmatory Study Supports Full Approval
The FDA converted Tecelra to traditional approval after reviewing the final clinical study report from the confirmatory ADP-0044-002 trial (NCT04044768, SPEARHEAD-1 Trial), which included data from Cohorts 1, 2, and 3. The study fulfilled the postmarketing requirement established under the accelerated approval pathway by providing additional evidence of efficacy through more precise estimates of overall response rate (ORR) and duration of response (DoR) assessed by independent review.
Participants were followed for at least 15 months to evaluate response durability. The review incorporated data from clinical studies associated with NCT04044768, NCT03132922, and NCT05642455.
The FDA also approved updated prescribing information, medication guide, and product labeling submitted with the supplemental biologics license application.
Pediatric Development Continues
Although the indication now includes adolescents aged 12 years and older with synovial sarcoma, pediatric development remains ongoing. The FDA waived studies in children younger than two years because of the rarity of MAGE-A4-positive tumors in this population. A deferred Pediatric Research Equity Act (PREA) requirement remains in place for Study ADP-0044-004, which is evaluating dosing, pharmacokinetics, safety, and antitumor activity in patients aged 2 to under 17 years with MAGE-A4-expressing solid tumors, including synovial sarcoma, malignant peripheral nerve sheath tumor, neuroblastoma, and osteosarcoma. Study completion is expected by April 2027, with the final report due in September 2027.
Companion Diagnostic Validation Remains a Postmarketing Commitment
The FDA also retained a postmarketing commitment requiring analytical and clinical validation of an FDA-authorized in vitro diagnostic test capable of accurately detecting MAGE-A4 antigen expression in adolescent patients. The company submitted a Premarket Approval (PMA) supplement to the FDA’s Center for Devices and Radiological Health (CDRH) in May 2026. The commitment will be fulfilled after CDRH approves the diagnostic and the FDA subsequently approves the related labeling update. The study report is due by September 30, 2026.
Clinical Implications
The conversion from accelerated to traditional approval strengthens the clinical evidence supporting Tecelra and confirms its benefit in advanced synovial sarcoma. The expanded indication extends access to eligible adolescent patients while ongoing pediatric studies and companion diagnostic validation continue to refine the therapy’s role in treating MAGE-A4-positive solid tumors.
What This Means for Patients
The FDA’s traditional approval confirms that Tecelra’s clinical benefit has been verified through confirmatory studies, providing stronger evidence of its effectiveness in advanced synovial sarcoma. The label expansion also allows eligible adolescents aged 12 years and older to access the therapy, offering a new treatment option for younger patients with this rare and aggressive cancer. Patients must still meet specific eligibility criteria, including prior chemotherapy, expression of the MAGE-A4 tumor antigen, and the presence of an eligible HLA-A*02 allele confirmed through companion diagnostic testing.
Reference
About the Writer
Disha Sanjay Jadhao (LinkedIn) is a pharmacy graduate and healthcare writer with a strong interest in clinical documentation and simplifying healthcare information for better reader understanding. She is enthusiastic, adaptable, and eager to take on new challenges while contributing to clear, accurate, and engaging medical and pharmaceutical content.